Meta-analysis of long-term outcome of symptomatic intracranial artery stenosis: comparison of stenting and medical therapy
10.3760/cma.j.issn.1673-4165.2017.07.004
- VernacularTitle:有症状颅内动脉狭窄长期转归的汇总分析:支架置入与药物治疗比较
- Author:
Hong GAO
1
;
Hua YANG
;
Xin XIANG
Author Information
1. 贵州医科大学
- Keywords:
Intracranial Arteriosclerosis;
Stents;
Secondary Prevention;
Stroke;
Treatment Outcome;
Meta-Analysis
- From:
International Journal of Cerebrovascular Diseases
2017;25(7):609-614
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the long-term outcomes between the stenting and the medical therapy in patients with symptomatic intracranial artery stenosis.Methods The articles that compared between the stenting and the medical therapy in patients with symptomatic intracranial artery stenosis searched from PubMed,Cochrane Lirary,EMBASE,and Google Scholar.A meta-analysis was conducted to evaluate risks of stroke recurrence and composite vascular events at 1 years,and composite vascular events risk and clinical outcomes (a good outcome was defined as the modified Rankin scale score 0-2) at 2 years after stent therapy or medical therapy.Results Six studies,comprising a total of 920 patients with symptomatic intracranial artery stenosis were included,458 in the stenting group,and 462 in the medical therapy group,their mean age was 61.8 years and 66％ were males.The meta-analysis showed that there were no significant differences in the risks of stroke recurrence (pooled odds ratio [OR] 1.74,95％ confidence interval [CI]0.95-3.20;P =0.07) and composite vascular events (pooled OR 1.27,95％ CI 0.74-2.16;P =0.39) at 1 year,as well as composite vascular events risk (pooled OR 1.30,95％ CI 0.89-1.89;P =0.17) and clinical outcome (pooled OR 1.37,95％ CI 0.32-5.82;P =0.67) at 2 years between stenting group and medical therapy group.Conclusions There were no significant differences in the risks of stroke recurrence and composite vascular events at 1 year,as well as composite vascular events risk and clinical outcome at 2 years after stenting or medical therapy in patients with symptomatic intracranial artery stenosis.
